As one of the three major types of genes in the RAS family, the KRAS mutation is one of the most common oncogenic mutations in cancer patients.

This article summarized the latest R&D progress of Phentolamine Mesylate, the Mechanism of Action for Phentolamine Mesylate, and the drug target R&D trends for Phentolamine Mesylate.

Replicate Bioscience has administered the first dosage of its RBI-4000 vaccine to a participant.

This article summarized the latest R&D progress of Norepinephrine Bitartrate, the Mechanism of Action for Norepinephrine Bitartrate, and the drug target R&D trends for Norepinephrine Bitartrate.

MEK, or Mitogen-Activated Protein Kinase Kinase, plays a crucial role in the human body as a key component of the MAPK signaling pathway.

This article summarized the latest R&D progress of Neostigmine Methylsulfate, the Mechanism of Action for Neostigmine Methylsulfate, and the drug target R&D trends for Neostigmine Methylsulfate.

Pierre Fabre Laboratories takes over Vertical Bio along with its ground-breaking, targeted therapy candidate for patients battling MET-altered Non-Small Cell Lung Cancer.

This article summarized the latest R&D progress of Milrinone Lactate, the Mechanism of Action for Milrinone Lactate, and the drug target R&D trends for Milrinone Lactate.

LSD1, also known as lysine-specific demethylase 1A, is an enzyme that plays a crucial role in the regulation of gene expression in the human body.

This article summarized the latest R&D progress of Midazolam Hydrochloride, the Mechanism of Action for Midazolam Hydrochloride, and the drug target R&D trends for Midazolam Hydrochloride.

Insilico Medicine and Exelixis, Inc. announced a licensing agreement allowing Exelixis to globally produce and market ISM3091, a promising USP1 inhibitor related to BRCA-altered cancers.

This article summarized the latest R&D progress of Metreleptin, the Mechanism of Action for Metreleptin, and the drug target R&D trends for Metreleptin.